Seer (NasdaqGS:SEER) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsDavid Horn - President and CFOKelly Gura - Principal of Investor RelationsOmid Farokhzad - Founder, Chairman, and CEOConference Call ParticipantsDan Brennan - Managing Director and Senior Equity Research AnalystOperatorGood day, and welcome to the Seer 4th quarter 2025 earnings conference call. Today, all participants will be in a listen-only mode. Should you need assistance during today's call, please signal for a ...

☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Registrant's telephone number, including area code: (781) 622-1000 Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which reg ...

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that humanoid robots could create a market worth $250 trillion by 2040, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is believed to be redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4][6] - Prominent figures in technology and investment, including Bill Gates and Warren Buffett, recognize AI as a significant technological advancement with the potential for substantial social benefits [8]

On profitability, South reported a fourth-quarter GAAP operating margin of 4.76% , down 10 basis points from the prior year, while non-GAAP operating margin was 7.42% , described as relatively flat year over year despite slightly lower gross margin driven primarily by product mix within the distribution and specialty groups.CFO Ron South said fourth-quarter global sales were $3.4 billion , up 7.7% year over year. Sales growth included 5.8% constant-currency growth, 1.9% benefit from foreign exchange, and 0. ...

Core Insights - Avantor, Inc. is a global provider of mission-critical products and services in the life sciences and advanced technologies sectors, competing with major players like Thermo Fisher Scientific and Merck KGaA [1] Financial Performance - Avantor's stock declined by 13.6% despite Q4 earnings exceeding expectations, with adjusted EPS at 22 cents, surpassing the Zacks Consensus Estimate by 4.8%, but down 18.5% year-over-year [3] - The company's revenue for the quarter was $1.66 billion, a 1.4% decrease year-over-year, yet it beat the Zacks Consensus Estimate by 3%, influenced by a 4.1% organic sales drop and cost pressures reflected in a 310 basis point contraction in adjusted operating margin [4] Insider Activity - Director SUMME GREGORY L executed a significant insider purchase of 100,000 shares at $9.40 each, increasing total holdings to 400,000 shares, which may signal confidence in the company's future prospects [2][6] Future Outlook - Avantor's 2026 guidance indicates expected challenges with organic revenue declines and EPS projected between 77 and 83 cents, although the company maintains a low debt-to-equity ratio of 0.0055 and a current ratio of 1.78, indicating strong liquidity [5]

Core Viewpoint - Bio-Techne Corporation announced leadership changes, with Steve Crouse appointed as President of the Diagnostics and Spatial Biology Segment, effective March 1, 2026, succeeding Dr. Matt McManus, who will assist in the transition [1]. Leadership Changes - Dr. Matt McManus will transition from his role as President of the Diagnostics and Spatial Biology Segment on March 1, 2026, but will remain with the company temporarily to ensure a smooth transition [1]. - Steve Crouse, previously Senior Vice President of the Analytical Solutions Division, has over 20 years of experience in life sciences and has been instrumental in driving growth and launching innovative platforms at Bio-Techne [1]. Company Background - Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics [1]. - The company generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide [1].

Core Insights - Thermo Fisher Scientific announced a strategic data collaboration with Datavant to enhance the connection between real-world data and clinical research for pharmaceutical and biotech companies [1] - The collaboration aims to facilitate the generation of stronger evidence more quickly by enabling secure connection and analysis of real-world data (RWD) [1] Company Overview - Thermo Fisher Scientific is recognized as the world leader in serving science, particularly in the clinical research sector [1] - The PPD™ clinical research business of Thermo Fisher will play a crucial role in this collaboration with Datavant [1] Industry Impact - The partnership is expected to streamline the process for pharmaceutical and biotech companies, making it easier to leverage real-world data in their clinical research efforts [1] - This initiative reflects a growing trend in the healthcare industry towards integrating real-world evidence into clinical research methodologies [1]

Core Viewpoint - Bio-Techne Corporation is a significant entity in the biotechnology sector, focusing on innovative tools and solutions for life sciences research and clinical diagnostics, competing with major players like Thermo Fisher Scientific and Danaher Corporation [1] Financial Performance - On February 4, 2026, Citigroup upgraded Bio-Techne's stock to a "Buy" rating at approximately $68.89, raising the price target from $70 to $80, indicating confidence in the company's growth potential [2] - Bio-Techne recently held its Q2 2026 earnings call, providing insights into its financial performance, revenue, profit margins, and strategic initiatives, which are crucial for understanding the company's current position and future outlook [3] Stock Performance - Currently, Bio-Techne's stock (TECH) is priced at $68.77, reflecting a 6.41% increase or $4.14, with a daily trading range between $61.70 and $69.92 [4] - Over the past year, the stock has fluctuated, reaching a high of $79.28 and a low of $46.01, indicating the dynamic nature of the stock market [4] Market Capitalization and Trading Volume - Bio-Techne's market capitalization is approximately $10.72 billion, with a trading volume of 3.59 million shares, reflecting the company's size and investor interest in its stock [5]

Group 1 - Revvity exceeded fourth-quarter estimates and forecasts for 2026 revenue and profit, driven by strength in its diagnostics business despite ongoing weakness in academic research funding [1][2] - The company anticipates adjusted profit per share for 2026 to be between $5.35 and $5.45, slightly above analysts' estimates of $5.32 [2] - Revvity projects annual sales for 2026 to be between $2.96 billion and $2.99 billion, surpassing the estimated $2.93 billion [2] Group 2 - Revvity's diagnostics unit achieved 7% organic growth, generating revenue of $390.1 million, significantly exceeding the $377.7 million forecasted by analysts [3] - The life sciences unit reported revenue of $382 million, slightly below the estimated $385.6 million [4] - Quarterly adjusted profit was $1.70 per share, surpassing the expected $1.55 per share, with total quarterly sales reaching $772.1 million, exceeding estimates of $761.3 million [4]

Investment Rating - The report maintains a BUY rating for Thermo Fisher with a new target price of US$670, up from the previous target price of US$654, indicating a potential upside of 15.8% from the current price of US$578.61 [2][8]. Core Insights - Thermo Fisher reported a strong performance in 4Q25, with revenue increasing by 7.2% year-over-year, marking the fastest quarterly growth in 2025. Adjusted EPS rose by 7.7%, surpassing Bloomberg consensus estimates by 2.2% and 1.9%, respectively [1][8]. - The company expects revenue growth of 3.9% to 5.9% and adjusted EPS growth of 5.9% to 8.4% for the full year 2026, reaffirming a long-term organic revenue growth target of 3%-6% [1][8]. Summary by Sections Financial Performance - For FY25, Thermo Fisher's revenue was US$44,556 million, with a year-over-year growth of 3.9%. The adjusted net profit was US$8,643 million, reflecting a growth of 3.1% [9][14]. - The company forecasts revenue of US$46,849 million for FY26, representing a growth of 5.1%, and adjusted net profit of US$9,130 million, which is a 5.6% increase [9][14]. Market Dynamics - The pharmaceutical and biotech sectors were the strongest client segments for Thermo Fisher in 2025, achieving mid-single-digit revenue growth for the year and high-single-digit growth in 4Q25. Management noted increased confidence among pharma companies in their relationships with governments [8]. - Biotech financing showed recovery in the second half of 2025, which is expected to drive revenue growth despite a typical lag of approximately six months between funding and R&D expenditure [8]. Strategic Acquisitions - In 2025, Thermo Fisher completed significant acquisitions, including Solventum's filtration and separation business for US$4.0 billion and Sanofi's sterile fill-finish facility for US$8.9 billion. These acquisitions are anticipated to enhance the company's global leadership in bioproduction and expand its capacity in the U.S. [8][9]. - Management expects adjusted EPS to grow by 7-9% in 2026 as a result of these strategic acquisitions [8]. Service Capabilities - Thermo Fisher's CDMO segment experienced strong growth in 2025, benefiting from limited sterile fill-finish capacity globally. The acquisition of Sanofi's facility is expected to secure growing orders for production in the U.S. [8]. - The integrated Accelerator business aims to improve project execution and reduce time-to-market for innovative drugs, thereby generating significant orders through differentiated service offerings [8].